Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

Active:	No
Cancer Type:	Hematopoietic Malignancies Leukemia Multiple Myeloma Myelodysplastic Syndromes (MDS)	NCT ID:	NCT03218683
Trial Phases:	Phase I	Protocol IDs:	D6910C00001 (primary) NCI-2017-01390
Eligibility:	18 - 85 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	AstraZeneca Pharmaceuticals LP
NCI Full Details:	http://clinicaltrials.gov/show/NCT03218683

Summary

This study is a multicenter, open-label, nonrandomized, sequential group, dose-escalation
study to assess safety, tolerability, pharmacokinetics and preliminary anti-tumor
activity of ascending doses of AZD5991 in subjects with relapsed or refractory
hematologic malignancies Part 1 of the study is monotherapy dose escalation. Closed
November 2020 Part 2 of the study is monotherapy expansion groups for relapsed/refractory
chronic lymphocytic leukaemia (CLL), AML/ myelodysplastic syndromes (MDS), and multiple
myeloma (MM). Closed November 2020 Part 3 is a sequential, dose-escalation study of the
combination of AZD5991 and venetoclax in subjects with relapsed/refractory AML

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.